• Novo Nordisk A/S, of Bagsvaerd, Denmark, said it submitted a marketing application in Europe and the U.S. for turoctocog alfa, a third-generation recombinant coagulation Factor VIII intended for prevention and treatment of bleeding with people with hemophilia A.